1. Gyre Therapeutics will present at H.C. Wainwright conference on Sept. 10. 2. The company focuses on fibrosis treatments, particularly liver fibrosis. 3. Gyre operates in the U.S. and China, with ongoing development programs. 4. They showcased their experience in mechanistic studies and clinical trials.
The forthcoming presentation at a major investment conference can attract investor interest, similar to past events where companies have seen price increases after gaining analyst attention or positive feedback from investors. Gyre's focus on innovative therapies places it in a promising sector of biopharmaceuticals, which often garners positive market sentiment.
The article discusses Gyre's presentation at a significant investment conference, which is crucial for visibility and investor engagement. This announcement indicates active company development and progress in their therapeutic pipeline, thus positively impacting investor confidence and stock performance.
The upcoming conference could lead to immediate investor reactions, and historical trends indicate a correlated short-term price response post-conference announcements within the biopharmaceutical sector. Such presentations often create buzz and speculative interest, potentially affecting stock prices promptly.
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025 at 12:30 p.m. ET.
To register in advance for the presentation webcast, sign up here.
The live webcast of the presentation will be also available on the Events and Presentations page of Gyre's website. A webcast replay will also be accessible following the live session.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the United States Gyre's strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People's Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY®, and development programs for F573, F528, and F230.
For Investors:
David Zhang
Gyre Therapeutics
david.zhang@gyretx.com
